Last updated: April 26, 2026
What does CA2679232 cover?
CA2679232 is a Canadian patent publication titled “COMBINATION THERAPY” (publication year 2014; Canadian application CA2679232). The claim set is structured around combining an anti-HIV agent with another anti-HIV agent to achieve improved efficacy and/or resistance profiles. The scope is defined through: (1) claim format that links drug identity to combination use, and (2) dependent claim partitions that narrow to particular agent classes, dosing regimens, and/or treatment contexts.
Scope map (high-level)
- Therapeutic area: anti-infective, HIV treatment
- Core scope element: a two-drug combination for administration to a patient
- Claim architecture: independent combination claim + dependent claims specifying
- the identity of the second agent (within defined chemical/functional boundaries),
- particular regimen parameters (timing and/or dosing schedule),
- and/or patient-treatment context.
What are the key independent claims (scope anchors)?
CA2679232’s independent claim(s) anchor the protection to a combination therapy regimen where:
- the combination includes an anti-HIV drug with a second anti-HIV drug, and
- the claim is directed to use of the combination for treating HIV infection (or HIV disease conditions) in a human patient.
In CA, combination patents typically use one of two independent claim structures:
- “A method of treating” using the defined drugs, or
- “Use of” the defined combination for treating HIV.
CA2679232 follows the combination-treatment model, with dependent claims narrowing the regimen and drug selection.
Independent claim scope (what it must do)
To fall within the independent claim, a product or regimen generally must:
- include both drug components as defined in the claim; and
- be administered for the claimed treatment purpose (HIV).
This creates a classic “two-component” infringement trigger. Single-agent therapy does not map to the independent combination use claim.
What dependent claim layers tighten the monopoly?
Dependent claims in CA2679232 are designed to fence off design-around pathways by limiting one or more of the following:
1) Which second anti-HIV agent is used
Dependent claims specify either:
- a particular named agent, or
- an agent defined by class, mechanism, or structural/functional limitation as recited in the specification and incorporated by reference.
2) How the regimen is administered
Dependent claims typically specify one or more of:
- sequential vs concurrent dosing,
- dose frequency,
- and/or a defined time window between doses.
3) Treatment context
Dependent claims often narrow to:
- initial therapy vs switch therapy,
- specific patient subgroups (where stated),
- or a defined disease stage or clinical endpoint.
4) Pharmaceutical form / composition framing
Some dependent claims in combination-treatment patent sets cover:
- pharmaceutical compositions containing one or both components; and/or
- kits containing components for combination use.
Where such claim formats exist, they can broaden infringement beyond the clinical regimen to manufacturing and packaging steps.
How broad is the claimed chemical and regimen space?
CA2679232’s breadth is driven by how precisely the claim language defines each drug component:
- If the claims name specific agents, scope is narrower but enforcement is more direct.
- If the claims use class-based or functional definitions, scope is wider but enforcement depends on whether an accused product meets the defined functional constraints.
For business planning, the most important practical question is not “HIV combination therapy” in general, but whether the claim language defines:
- exact compounds, or
- a class boundary (example: inhibitor type, target, or mechanism).
What is the patent landscape in Canada around CA2679232?
The Canadian landscape for HIV combination therapies is typically dense because patent families cover:
- individual drugs (compound patents),
- combinations (use/regimen patents),
- and incremental improvements (dose regimens, adherence, resistance patterns, and formulation).
CA2679232 sits in the combination-use tier rather than the foundational compound tier (based on its title and claim structure).
Landscape layers affecting freedom-to-operate (FTO)
A) Compound patents for each component
If a generic seeks entry to a combination regimen protected by CA2679232, it still must clear:
- patents covering the individual drugs, and
- any Canadian divisional or continuation patents in the same family.
B) Combination-use patents like CA2679232
These often block:
- method-of-use approvals and labeling,
- and may constrain what the generic can claim or market (depending on whether the generic leverages medicinal ingredient authorizations and whether Orange Book analogs apply in Canada via patent lists and regulatory notices).
C) Formulation and dosing regimen patents
Even if a company clears compound patents, it must check:
- formulation patents covering fixed-dose combinations,
- dosing frequency/regimen patents,
- and kit/packaging patents.
How do Canadian regulatory and listing mechanics interact with CA2679232?
In Canada, drug patents can become operationally relevant when they are:
- listed against a drug in the regulatory patent register (patent listing process connected to marketing authorization),
- and subject to notices that drive litigation timelines (commonly through the PM(NOC) framework).
For combination-use patents, the litigation and regulatory leverage often focuses on:
- whether the generic’s planned label and dosing instructions would infringe the patented method-of-use claims,
- whether a proposed use falls within the patented regimen parameters.
Even if a formulation is not the same, a method-of-use claim can still be triggered if the marketed regimen matches the patent’s defined combination and administration boundaries.
What would be the most relevant infringement “match” scenarios?
A regimen or product is most likely to raise risk if it matches three elements simultaneously:
-
Drug identity match
The regimen includes both drugs as defined in the claim.
-
Purpose match
The intended use is for the claimed HIV treatment context.
-
Regimen match
The dosing schedule, order, timing, or regimen boundaries align with dependent claim limitations.
Design-around pressure points
Companies seeking to avoid CA2679232 scope generally target one of:
- replace one component with a different agent outside the claim boundary,
- alter regimen order or timing so it does not meet dependent regimen definitions,
- or market a non-covered use (labeling strategy), if the claim set supports such separation.
The effectiveness depends on how the dependent claims are drafted and whether they are strict to a regimen schedule.
How does CA2679232 compare to typical HIV combination patents in Canada?
Compared to broad “combination therapy” patents that define only drug classes, CA2679232’s practical value generally tracks claim drafting specificity:
- If it names specific agents, enforcement aligns with product labeling and actual administered regimens.
- If it uses class descriptors, enforcement becomes more fact-intensive and often turns on mechanism and whether the accused agent falls within the recited functional limitation.
In Canada, where method-of-use claims are common, “planned use” and “indication” issues often matter as much as actual formulation identity.
What does CA2679232 imply for generic entry timing?
For a generic or follow-on combination entrant, CA2679232 functions as an additional barrier beyond:
- the expiry of compound patents, and
- any other combination-use patents.
Entry timing hinges on:
- whether CA2679232 is listed against the reference product(s),
- whether CA2679232 is still in force,
- and whether the generic can generate a non-infringing path (label carve-out, regimen change, or invalidity/non-infringement positions).
Where is the strongest enforcement leverage likely to come from?
In practice, strong leverage typically comes from:
- independent method-of-use claims that recite exact drug combinations; and
- dependent regimen claims that constrain dosing schedule.
If the claim set includes:
- “use” language tied to specific regimen parameters,
- and fixed-dose or kit framing,
then enforcement can reach both prescribers and downstream commercialization.
Key Takeaways
- CA2679232 is a Canadian combination-therapy patent focused on anti-HIV treatment through a two-drug combination and associated regimen limitations.
- The core infringement trigger is a regimen that satisfies three elements: both defined drug components, the claimed HIV treatment purpose, and (for dependent claims) the specific administration and schedule.
- The Canadian landscape around CA2679232 typically includes a layered set of barriers: compound patents for each component, other combination-use patents, and formulation or dosing regimen patents.
- For FTO and entry planning, CA2679232 is best treated as an added method-of-use risk that can constrain labeling, regimen design, and commercialization even when a company has cleared some compound-IP.
FAQs
1) Is CA2679232 a compound patent or a combination-use patent?
It is a combination therapy (use/regimen) patent, centered on two-drug anti-HIV therapy rather than a foundational single-compound monopoly.
2) What is the main claim element that creates infringement risk?
The main risk comes from the requirement to use both drug components in the defined combination for the claimed HIV treatment purpose.
3) Can a company avoid CA2679232 by using a single agent instead of the combination?
A single-agent regimen generally does not match a combination-use claim because the claims are structured around two-agent combination therapy.
4) If dosing is changed, does that reduce risk?
Risk can drop if the change moves outside the dependent claims’ regimen limitations, especially where the patent specifies timing, sequence, or dose frequency.
5) How does CA2679232 affect generic or follow-on combination development in Canada?
It can restrict generic entry through listed patent leverage and method-of-use infringement exposure, even when the individual drug compound protections are separately considered.
References
[1] Canadian Intellectual Property Office. CA2679232 (publication record and bibliographic details).
